Revenue - Revenue from contracts with customers (Details) |
1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2022
USD ($)
$ / £
|
Nov. 30, 2022
USD ($)
|
Dec. 31, 2023
USD ($)
$ / £
|
Sep. 30, 2023
USD ($)
|
Dec. 31, 2023
USD ($)
$ / £
|
Dec. 31, 2022
USD ($)
$ / £
|
Dec. 31, 2021
USD ($)
$ / £
|
Jun. 30, 2023
USD ($)
|
Jan. 01, 2022
USD ($)
|
|
| Revenue | |||||||||
| Revenue | $ 60,281,000 | $ 27,148,000 | $ 6,149,000 | ||||||
| Deferred revenue decrease | 6,379,000 | 15,010,000 | |||||||
| Deferred revenue | $ 184,412,000 | $ 178,033,000 | 178,033,000 | $ 184,412,000 | 199,422,000 | $ 184,412,000 | |||
| Amount of increase in deferred income caused by the change in the exchange rate | $ 7,174,000 | $ (20,601,000) | |||||||
| Exchange rate | $ / £ | 1.21 | 1.27 | 1.27 | 1.21 | 1.35 | ||||
| Revenue recognized in the period | $ 59,072,000 | $ 17,648,000 | |||||||
| Development revenue | |||||||||
| Revenue | |||||||||
| Revenue | 60,281,000 | $ 27,148,000 | $ 6,149,000 | ||||||
| GSK Collaboration And License Agreement | |||||||||
| Revenue | |||||||||
| Upfront payment by GSK for Termination and Transfer Agreement | $ 9,613,000 | ||||||||
| Milestone payments received | $ 15,226,000 | $ 3,727,000 | |||||||
| Genentech, Inc. | |||||||||
| Revenue | |||||||||
| Milestone payments received | $ 20,000,000 | $ 15,000,000 | |||||||
| Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements | $ 312,747,000 | $ 312,747,000 | |||||||
| X | ||||||||||
- Definition Amount of decrease in obligation to transfer good or service to customer for which consideration has been received or is receivable. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable, due to change in exchange rate. No definition available.
|
| X | ||||||||||
- Definition Represents cash received upon achievement of various development milestones under license agreements. No definition available.
|
| X | ||||||||||
- Definition Amount of upfront payment by GSK for Termination and Transfer Agreement. No definition available.
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|